Fmr Llc ownership in DUL / Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

DE ˙ XTRA ˙ US02043Q1076

251,80 € ↑6,70 (2,73%)

2026-06-03
DEL PRIS

Security	DE:DUL / Alnylam Pharmaceuticals, Inc.
Institution	Fmr Llc
Latest Disclosed Ownership	16,834,094 shares
Ownership	12.80%

2025-11-05 - Fmr Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 16,834,094 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL). This represents 12.8 percent ownership of the company. In their previous filing dated 2024-11-12 , Fmr Llc had reported owning 14,755,604 shares, indicating an increase of 14.09 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-11-05	2025-11-05	13G/A	14,755,604	16,834,094	14.09	12.80	11.46
2024-11-12	2024-11-12	13G/A	13,265,378	14,755,604	11.23	11.48	9.54
2024-08-12	2024-08-12	13G/A	10,342,397	13,265,378	28.26	10.48	27.25
2024-02-09	2024-02-09	13G/A	13,542,825	10,342,397	-23.63	8.24	-25.13
2023-02-09	2023-02-09	13G/A	17,940,020	13,542,825	-24.51	11.01	-26.63
2022-02-09	2022-02-09	13G/A	16,091,945	17,940,020	11.48	15.00	8.30
2021-02-08	2021-02-08	13G/A	16,720,375	16,091,945	-3.76	13.85	-7.65
2020-02-07	2020-02-07	13G/A	15,154,553	16,720,375	10.33	15.00	-0.01
2019-02-13	2019-02-13	13G/A	14,875,621	15,154,553	1.88	15.00	0.00
2018-02-13	2018-02-13	13G/A	12,872,080	14,875,621	15.57	15.00	0.00
2017-02-14	2017-02-14	13G/A	12,710,356	12,872,080	1.27	15.00	0.00
2016-02-12	2016-02-12	13G/A		12,710,356		15.00
2015-02-13	2015-02-13	13G/A		11,539,663		15.00
2014-02-14	2014-02-14	13G/A		9,514,511		15.00
2013-02-14	2013-02-14	13G/A		7,862,160		15.00
2012-02-14	2012-02-14	13G/A		4,796,976		11.23

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	14,579,166	-1,322,983	-8.32	4,823,809	-23.72	0.0505
2026-02-17	2025-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,902,149	-865,476	-5.16	6,323,489	-17.30	0.3224
2025-11-13	2025-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	16,767,625	961,104	6.08	7,646,037	48.34	0.3976
2025-08-14	2025-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,806,521	496,661	3.24	5,154,348	24.68	0.2907
2025-05-12	2025-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,309,860	1,823,957	13.52	4,133,968	30.27	0.2639
2025-02-13	2024-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,485,903	-1,186,369	-8.09	3,173,368	-21.36	0.1894
2024-11-13	2024-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	14,672,272	2,508,234	20.62	4,035,315	36.52	0.2455
2024-08-13	2024-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,164,038	2,196,042	22.03	2,955,861	98.42	0.1892
2024-05-13	2024-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,967,996	-344,360	-3.34	1,489,717	-24.53	0.1000
2024-02-13	2023-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	10,312,356	-969,050	-8.59	1,973,888	-1.20	0.1516
2023-11-13	2023-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	11,281,406	-1,211,094	-9.69	1,997,937	-15.80	0.1727
2023-08-11	2023-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,492,500	-678,335	-5.15	2,372,825	-10.07	0.1989
2023-08-11	2023-03-31	13F/A-1	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,170,835	-341,248	-2.53	2,638,382	-17.84	0.2413
2023-05-11	2023-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,170,835	-341,248		2,638,382		0.2413
2023-02-13	2022-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,512,083	562,325	4.34	3,211,146	23.89	0.3190
2022-11-10	2022-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,949,758	-1,374,991	-9.60	2,592,024	24.06	0.2703
2022-08-12	2022-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	14,324,749	-1,720,567	-10.72	2,089,265	-20.26	0.2082
2022-05-13	2022-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	16,045,316	-1,894,704	-10.56	2,620,040	-13.88	0.2093
2022-02-14	2021-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	17,940,020	113,092	0.63	3,042,268	-9.62	0.2246
2022-02-14	2021-09-30	13F/A-1	ALNYLAM PHARMACEUTICALS	COM	02043Q107	17,826,928	195,199	1.11	3,365,903	12.61	0.2670
2021-11-15	2021-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	17,826,928	195,199		3,365,903		0.2669
2021-08-13	2021-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	17,631,729	81,828	0.47	2,988,931	20.63	0.2342
2021-05-14	2021-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	17,549,901	1,457,954	9.06	2,477,870	18.48	0.2116
2021-02-08	2020-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	16,091,947	-376,981	-2.29	2,091,470	-12.78	0.1861
2020-11-13	2020-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	16,468,928	-605,703	-3.55	2,397,876	-5.18	0.2424
2020-08-24	2020-06-30	13F/A-1	ALNYLAM PHARMACEUTICALS	COM	02043Q107	17,074,631	269,322	1.60	2,528,923	38.25	0.2781
2020-08-13	2020-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	17,074,631	269,322		2,528,923		62,128.2375
2020-05-14	2020-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	16,805,309	84,934	0.51	1,829,258	-5.01	0.2533
2020-02-07	2019-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	16,720,375	39,228	0.24	1,925,686	43.55	0.2125
2019-11-13	2019-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	16,681,147	700,631	4.38	1,341,499	15.69	0.1609
2019-08-13	2019-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,980,516	34,850	0.22	1,159,546	-22.18	0.1354
2019-05-13	2019-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,945,666	791,113	5.22	1,490,122	34.86	0.1785
2019-02-13	2018-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,154,553	54,637	0.36	1,104,919	-16.39	0.1514
2018-11-09	2018-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,099,916	21,555	0.14	1,321,544	-11.01	0.1487
2018-08-10	2018-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,078,361	52,653	0.35	1,485,068	-17.02	0.1753
2018-05-14	2018-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	15,025,708	150,087	1.01	1,789,562	-5.31	0.2124
2018-02-12	2017-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	14,875,621	1,115,616	8.11	1,889,948	16.90	0.2215
2017-11-13	2017-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,760,005	36,852	0.27	1,616,663	47.70	0.1955
2017-08-29	2017-06-30	13F/A-1	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,723,153	815,270	6.32	1,094,559	65.46	0.1360
2017-08-11	2017-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	13,723,153	815,270		1,094,559
2017-05-11	2017-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,907,883	35,803	0.28	661,530	37.27	0.0840
2017-02-10	2016-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,872,080	13,385	0.10	481,931	-44.70	0.0644
2016-11-14	2016-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,858,695	24,615	0.19	871,562	22.38	0.1161
2016-08-11	2016-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,834,080	30,785	0.24	712,163	-11.39	0.0972
2016-05-16	2016-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,803,295	92,939	0.73	803,662	-32.84	0.1112
2016-02-12	2015-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,710,356	18,087	0.14	1,196,553	17.31	0.1610
2015-11-10	2015-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,692,269	49,865	0.39	1,019,951	-32.70	0.1452
2015-08-25	2015-06-30	13F/A-1	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,642,404	78,383	0.62	1,515,445	15.51	0.1942
2015-08-13	2015-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,642,404			1,515,445
2015-05-14	2015-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	12,564,021	1,024,358	8.88	1,311,935	17.21	0.1671
2015-02-17	2014-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	11,539,663	86,441	0.75	1,119,347	25.14	0.1457
2014-11-14	2014-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	11,453,222	120,214	1.06	894,497	24.95	0.1211
2014-08-14	2014-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	11,333,008	1,745,486	18.21	715,906	11.22	0.0960
2014-05-15	2014-03-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,587,522	74,711	0.79	643,707	5.19	0.0894
2014-02-13	2013-12-31	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,512,811	70,011	0.74	611,959	1.24	0.0865
2013-11-14	2013-09-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,442,800	117,145	1.26	604,434	109.01	0.0926
2013-09-24	2013-06-30	13F/A-1	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,325,655	9,325,655		289,188		0.0473
2013-08-14	2013-06-30	13F	ALNYLAM PHARMACEUTICALS	COM	02043Q107	9,325,655			289,188		0.0473

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.